Summary: TAS-102, a new oral drug, is composed of an antitumor drug, a,a,a-tri‰uorothymidine (FTD), and its metabolic inhibitor, 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1H,3H )-pyrimidinedione hydrochloride (TPI). It has been reported that the oral administration of TAS-102 increases the AUC of FTD in rodents and monkeys in diŠerent manners. In this study, a pharmacokinetic model was developed, in an attempt to evaluate the bioavailability of FTD in these animals after the co-administration of TPI. Since TPI inhibits FTD metabolism competitively, a time-dependent as well as concentration-dependent model for the hepatic intrinsic clearance of FTD was developed including the time courses of both FTD and TPI. Based on this modeling, we were able to quantitatively explain the TPI dose-dependent enhancement of AUC of FTD in monkeys, while little increase was observed in rats. These results are consistent to observations that thymidine phosphorylase (TPase) is predominantly expressed in monkeys; while uridine phosphorylase (UPase) is superior to TPase in rats. Since TPase is also predominantly expressed in humans, the pharmacokinetic model developed in this study can be used to explain the bioavailability of TAS-102 in humans.
Introduction a,a,a-tri‰uorothymidine (FTD) has potent antitumor and antiviral activities in humans, [1] [2] [3] [4] but it is eliminated from the body with a half life of 12¿18 minutes. 5, 6) Uridine phosphorylase (UPase) and thymidine phosphorylase (TPase) are enzymes that are responsible for the rapid clearance of FTD in mammals. [7] [8] [9] [10] It has been reported that TPase is expressed predominantly in monkeys and humans, while rodents have high UPase activities. [11] [12] [13] [14] TAS-102, a new antitumor drug, contains a combination of FTD and a speciˆc TPase inhibitor, 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1H,3H )-pyrimidinedione hydrochloride (TPI), in molar ratio of 2:1 to increase the area under the curve (AUC) of FTD following its oral administration in animals. 15, 16) As expected, the AUC for FTD after an oral administration of TAS-102 is increased, to some extent, in mice, while the increase is more dramatic in monkeys due to the diŠerences in the expression of TPase and UPase among animals. 15) In this study, we report on the development of a pharmacokinetic model to evaluate the species speciˆcity of the bioavailability of FTD in rats and monkeys in the presence of TPI. Hepatic clearance appears to play an important role in predicting the bioavailability (F) of FTD, and the inhibitory eŠect by TPI on FTD metabolism should also be quantiˆed to permit the precise estimation of F in the presence of TPI.
In this report, hepatic intrinsic clearance was evaluated using a Michaelis-Menten type kinetics and a linear method. Simulations of the AUC after the administration of FTD with diŠerent doses of TPI revealed a remarkable dose-dependent increase of TPI in monkeys but only a slight increase in rats.
The results of the present study permit the quantitative evaluation of the species dependent enhancement in the AUC for FTD between rats and monkeys, with the co-administration of TPI.
Materials and Methods
Chemical: TPI and 1-methyl-5-chloro-6-(pyrrolidine-1-yl)methyl-2,4(1H,3H )-pyrimidinedione (TAS-1-1543), an internal standard of TPI were synthesized at the Taiho Pharmaceutical Co., Ltd. FTD was purchased from the Yuki Gosei Kogyo Co., Ltd.
14 C-FTD labeled at position C-2 of the pyrimidine ring, with a speciˆc activity of 2.072 GBq W mmole was purchased from Moravek Biochemicals Inc. The radiochemical purity was in excess of 97z. 5-iodo-2?-deoxyuridine (IDU), an internal standard of FTD was purchased from Tokyo Chemical Industry Co., Ltd. a,a,atri‰uorothymine (FTY) was purchased from Tokyo Kasei Kogyo Co., Ltd. All other chemicals used were commercially available products.
Animals: Male rats (5¿7 weeks of age, SpragueDawley(Crj:CD) strain IGS) were purchased from Charles River Japan. Male Cynomolgus monkeys (weighed between 2.2 and 6.4 kg) were purchased from KASHO Co., Ltd, KEARI Co., Ltd or Covance Research Product.
Pharmacokinetic studies in rats: The doses of TAS-102 are expressed in terms of FTD. We observed that the plasma concentrations of FTD and TPI in rats were not aŠected by their condition (fasted or nonfasted). Thus, we estimated the pharmacokinetic parameters for FTD and TPI from the time-courses without taking these conditions into account. 3) FTD, i.v. administration To determine FTD concentrations in plasma and the amount of FTD (z of dose) in urine, FTD 30 mg W kg was administered intravenously as a bolus via the femoral vein to fasted male monkeys (n＝3). Blood samples were withdrawn at 3, 10, 30 min and 1, 1.5, 2 hr post-dose. The animals were housed in metabolic cages to permit the collection of urine samples at intervals of 0-2, 2-4, 4-6, 6-8, and 8-24 hr post-dose.
Bioanalytical method for the determination of FTD and TPI: Representative bioanalytical methods are as follows: TAS-1-1543 and IDU were used as internal standards. A 0.5 mL aliquot of plasma was added to 0.1 mL of distilled water and 0.3 mL of 0.1 M hydrochloric acid was added after spiking with 0.1 mL of the internal standard solution. The sample was applied to a Bond Elut PRS column, and eluted with 2 mL of 2z ammonia in methanol after washing with 2 mL of water and 2 mL of methanol. The eluate was reconstituted in 0.2 mL of acetate buŠer (pH 4.3) after drying and a 30 mL portion was then injected into the HPLC for the determination of TPI. The pass through and the washing fractions were combined, 0.02 mL of 1 M hydrochloric acid was added, and the resulting solution applied to an AG 50W-X4 cation exchange column. The column was washed twice with 2 mL of water, and again, the pass through and washing fractions were combined and neutralized with 1 mL of alkaline buŠer (50 mM carbonate buŠer (pH 10.0) W 1 M sodium hydroxide＝3 W 1) in ice bath. The resulting solution was immediately applied to an AG1-X4, anion exchange column, and eluted three times with 2 mL of 0.3 M acetic acid-methanol solution after washing twice with water and twice with methanol. The eluate was reconstituted with HPLC mobile phase after drying and 50 mL of portion was then injected into the HPLC for the determination of FTD.
The HPLC analysis was performed using a Waters 600E HPLC system with ultraviolet detection. FTD was separated with a TSK gel ODS-80TM column (4.6 mm I.D.×150 mm L, Tosoh) under the following chromatographic conditions: mobile phase, 10 mM acetate buŠer (pH 3.5) W methanol＝86 W 14 (volz); ‰ow rate, 1.0 mL W min; monitoring wavelength, 265 nm. TPI was separated on a Mightysil PR-18 column (4.6 mm I.D.× 150 mm L, Kanto Chemicals) under the following chromatographic conditions: mobile phase, 7 mM sodium 1-hexanesulfonate in 10 mM acetate buŠer (pH 4.3) W acetonitrile＝92 W 8 (volz); ‰ow rate, 1.0 mL W min; monitoring wavelength, 276 nm. The analytical range in concentrations were 10¿10000 ng W mL for both FTD and TPI. The accuracies and precisions for concentrations of 20, 400 and 8000 ng W mL were ranged in -0.9¿4.0z and 0.6¿1.4z for FTD, and 0.5¿2.5z and 1.1¿2.4z for TPI respectively. Urine samples were analyzed using similar procedures.
The plasma and urine samples after the dosing of 14 Clabeled compound were deproteinized with methanol. The extract was reconstituted in a deˆned volume of mobile phase, and the solution was then subjected to preparative HPLC using an LCSS-905 system (Japan Spectroscopic), equipped with a Chemcosorb 300-5C18 (4.6 mm I.D.×250 mm L) column (Chemco) under the following chromatographic conditions: mobile phase, 20 mM phosphate buŠer (pH 7.2) W acetonitrile＝96 W 4 (volz); ‰ow rate, 0.5 mL W min; monitoring wavelength, 300 nm. The HPLC eluate was collected in a minivial at 30 sec intervals for liquid scintillation counting. Counting e‹cacy was corrected by a Channel Ratio method using external standard sources. The background radioactivity was determined using the HPLC eluate before each injection. The radioactivity concentrations were converted into ng equivalent W mL to FTD.
Enzyme kinetics studies of TPI for the inhibition of FTD metabolism: Enzyme kinetics studies of TPI for the inhibition of FTD metabolism were carried out using cytosols prepared from the commercially available liver S9 of a Sprague-Dawley rat and a Cynomolgus monkey (XenoTech, USA). The cytosols obtained from the rat and monkey were prepared with a protein content of 0.5 mg W mL with 100 mM Tris-HCl buŠer (pH 7.4). When the kinetic parameters were determined without inhibition by TPI, 0.14 mL of 143 mM phosphate buŠer (pH 7.4) and 0.02 mL of FTD solution were combined and pre-incubated at 379 C for 1 min, and then incubated for 3 min after the addition of 0.04 mL of the cytosol solution. The reaction conditions were as follows, concentration of phosphate buŠer; 100 mM, protein content; 0.1 mg W mL, concentration of FTD; 25, 50, 100, 250, 500 and 1000 mM for the rat, 10, 25, 50, 100, 250 and 500 mM for the monkey, and were triplicated for each concentration. Under these conditions, it would be expected that most of the FTD in the reaction mixtures was present in the free form, based on ultraˆltration data (data not shown). The reaction was stopped by the addition of 0.2 mL of 10z perchloric acid, and then vortexed for 5 sec. The supernatant from the incubated solution after centrifugation was directly analyzed by HPLC to determine the concentration of FTY, the main metabolite of FTD, an inactive form degraded by TPase. HPLC analyses were performed using the LC-10AD system (Shimadzu), equipped with a Hydrosphere C18 (4.6 mm I.D.×100 mm, i.d.; 3 mm) (YMC) under the following chromatographic conditions: mobile phase, 0.06z tri‰uoroacetate W methanol ＝76 W 24 (volz); ‰ow rate, 1.0 mL W min; monitoring wavelength, 261 nm. When the kinetic parameters were determined with inhibition by TPI, 0.12 mL of 143 mM phosphate buŠer (pH 7.4), 0.02 mL of TPI, the same buŠer solution (ˆnal concentration of TPI; 10 and 20 nM for rat, 5 and 10 nM for monkey), and 0.02 mL of FTD solution were combined, and then subjected to the same procedure as described above. Since it was observed that the bound fraction of TPI in the plasma was less than 7z, we assumed that most of the TPI in the reaction mixtures was also present in the free form. Kinetic parameters were determined by the non-linear least square program (MULTI) 17) using the damping Gauss-Newton method weighted 1 W C 2 , and initial conditions were estimated with the Simplex method. In the case of without inhibition by TPI, the following Michaelis-Menten Eq. (1) was used:
where [S ], [ , V max and K m represent the concentration of FTD, the formation rate of FTY, the maximum velocity and the Michaelis constant, respectively. In case of with the inhibition of TPI, Eq. (2) for competitive inhibition 15) was used:
where [I ] is the concentration of TPI, to determine Ki the inhibition constant of TPI.
Determination of Blood W Plasma concentration ratios (Rb) of FTD: For monkeys, blood was obtained from 3 individuals and mixed. A 10 mL aliquot of 14 C-FTD solution was added to 490 mL of the mixed blood to givê nal concentrations of 0.1, 1, 10 and 100 mg W mL. For rats, blood was obtained from 2 individuals 11 weeks of age and mixed. A 20 mL aliquot of 14 C-FTD solution was added to 980 mL of the mixed blood to giveˆnal concentrations of 0.3, 3, 30 and 350 mg W mL. Since it was shown that TPase is identical to platelet-derived endothelial cell growth factor, 18, 19) the same reaction described below was also conducted in the presence of TPI. However, the results obtained were the same as in the absence of TPI, therefore we used these values for simulations. After incubation for 10 min, aliquots of blood samples were centrifugued to obtain plasma samples. The blood samples were then dissolved in 0.3-0.4 mL soluen-350 (Packard) W isopropyl alcohol mixture (1 W 1), decolorized with hydrogen peroxide and 10 mL of liquid scintillator added. The plasma samples were dissolved with 0.2 mL soluen-350 W isopropyl alcohol mixture (1 W 1) and 10 mL liquid scintillator added. The radioactivity of these samples was measured with a liquid scintillation counter (2000CA, Packard).
Model development for FTD and TPI in rats and monkeys: PK parameters were estimated byˆtting the time courses for plasma concentration curves in rats and monkeys after oral administrations of 50 mg W kg and 30 mg W kg of TAS-102, respectively, with the MULTI 17)ˆx ing all weights as 1 W C 2 , and the initial conditions were estimated with the Simplex method.
Estimation of systemic, renal and hepatic clearances (CLtot,b, CLr,b and CLh,b) in rats and monkeys: The area under the curve (AUC), the bioavailability and the systemic clearance were calculated using the equations below.
where A, B, alpha and beta are constants, and kel, ka ( W min), AUCpo, AUCiv (mg･mL W min), F, D (mgW kg) and CL tot (mL W min) represent the elimination rate constant, the absorption rate constant, the area under the curve after oral and intravenous administration, the 
b. Time course of FTD in monkeys wasˆtted with the 1-compartment model as follows:
c. AUC iv in rats and monkeys were obtained by intravenous administration of 50 and 30 mg W kg of TAS-102, respectively. d. F in rats and monkeys were calculated by using AUC iv and AUC po of each animal after administration of 50 and 30 mg W kg of TAS-102, respectively. bioavailability, the dose, and the systemic clearance, respectively. AUCiv in rats and monkeys were obtained by the intravenous administration of 50 and 30 mg W kg of TAS-102, respectively. Renal clearance (CL r ) was estimated from the FTD excreted into the urine after the oral (rats) or intravenous (monkeys) administration according to the following equation:
monkeys: CLr＝ X u AUCiv (10) where Xu (mg W kg) is the urinary excreted FTD. Since we observed a TPI-dependent increase in urinary excretion of FTD in both rats and monkeys, the relationship between the CLr and the TPI dose was used to estimate the CLrs for a precise simulation. Assuming that FTD is eliminated from the body exclusively by the metabolism in the liver, excretion from the kidney, hepatic clearance (CL h ) can be represented as follows:
We assumed that the metabolism of FTD occurs only in the liver for the simplicity of the analysis. The metabolism in the gastrointestinal tract (G.I.) was neglected in this modeling (f g.i. ＝1).
Simulation of non-linear FTD disposition in animals:
Since CLint,h is a non-linear function of the concentration for both FTD and TPI, CLint,h can be estimated using the time course for FTD and TPI. In this simula- tion, the CLint,h was calculated numerically using the time courses for C b and I, which represent the concentration of FTD and TPI, respectively, in the blood, based on the ‰ow model in Fig. 1 . In this analysis, CLint,h was estimated using a scaling factor (a) between in vitro and in vivo, and a correction factor (b ), which is a concentration independent component especially in the case of rats:
＋b (12) where I(t), C b (t) and f b represent the concentration of TPI and FTD in the blood, as functions of time, and the unbound fraction of FTD in the blood, respectively. The term b was required only in rats to represent the contribution of UPase which is predominantly expressed in rodents. 15) It was assumed to be a constant since its Km value (57-958 mM) 14) was much higher than the concentration of FTD in blood (¿8 mM). The a and b terms were estimated by simulating the time course for FTD in rats or monkeys.
Since the liver was assumed to be the only compartment where FTD is metabolized, bioavailability, which is also a function of time, was estimated as follows, assuming fg.i.＝1 and a well-stirred model:
where F(t), fh(t), fg.i. and Qh (mL W min) are the bioavailability, the availability in the liver, the availability in the G.I. tract, and the hepatic blood ‰ow, respectively.
Concerning the other parameters, the values summarized in Tables 1 and 2 were used. The AUC was calculated numerically by the trapezoidal formula from time 0 to 240 (rats) or 720 (monkeys).
Simulations of non-linear drug disposition of FTD were performed with STELLA 5.1.1 (High Performance Systems, Inc.). EŠect of the co-administration of TPI on the time course of FTD: For a quantitative evaluation of the eŠect of TPI on FTD kinetics in rats and monkeys, the time courses for FTD in blood after the oral co-administration of several doses of TPI were simulated based on the model constructed above (Fig. 1) .
Results
PK parameters of rats and monkeys: PK parameters for FTD and TPI were estimated in rats or monkeys following the oral administration of TAS-102 using MULTI, 17) and the results are shown in Fig. 2 and the resulting parameters are summarized in Table 1 .
The kinetic parameters, K m and V max , for hepatic metabolism were obtained from the in vitro experiments on the inhibition of FTD metabolism by TPI in the hepatic cytosol in rats and monkeys ( Table 2) .
To determine the scaling factor in Eq. (12), a was Fig. 3 . Relationship between the dose of TPI and CL r,b . The values were calculated as described in the Methods section and are summarized in Table 3 . ■, ○, and ◇ represent renal clearance, hepatic clearance and systemic clearance, respectively. A) In rats, the equation representing the relationship between the renal clearance and the dose of TPI was obtained as follows:
In monkeys, the equation was as follows:
These relationships were used in the simulations. estimated from the observed time course for FTD in blood, based on the ‰ow model in Fig. 1 . In the case of monkeys, it was found that the contribution of UPase in vitro was minimal, and, as a result, b wasˆxed at 0, while in rats, UPase contributed signiˆcantly according to the in vitro experiments, [11] [12] [13] [14] and both a and b were estimated from the observed data by simulation. The AUC was calculated according to Eq. (14) .
CLs of rats and monkeys: A dose-dependent eŠect of TPI on the CL r of FTD in both rats and monkeys was found, as shown in Fig. 3 and Table 3 . This relationship wasˆtted to a linear equation and used in the following simulations.
Simulation of FTD disposition:
The parameters used in simulation (Tables 1 and 2) were fundamentally based on the PK parameters for each animal obtained from the PK analysis of plasma drug concentrations following the oral administration of TAS-102. CLint,h and F are non-linear as well as time dependent, and are functions of both FTD and TPI blood concentrations according to Eq. (12) and (13), respectively. The other parameters were constant.
The simulated AUCs in both rats and monkeys were close to the observed values (AUCsimulated W AUCobserved were 0.9 and 0.8 in rats and monkeys, respectively.).
EŠect of TPI on the FTD availability: The eŠect of TPI co-administration with FTD on the bioavailability of FTD after oral administration was simulated based on the parameters obtained. The time courses for FTD after the oral administration of diŠerent doses of TPI were simulated (Fig. 4) . A remarkable TPI dosedependent enhancement (up to 80 fold) on the AUC of FTD in monkeys was found, while the increase was minimal in rats (Fig. 5) .
Discussion
The e‹cacy of FTD as an antitumor and antivirus drug has been clearly demonstrated in clinical studies, [1] [2] [3] [4] however, its rapid elimination from the human body (half life of 12¿18 min) has limited its clinical application. 5, 6) TPI, a speciˆc inhibitor of TPase, plays an important role in FTD metabolism, and, when combined with FTD as TAS-102 it increases the e‹cacy of FTD.
15) It was observed that the oral administration of TAS-102 in experimental animals resulted in a dramatic increase in the AUC for FTD compared to the administration of FTD alone. 15) In this study, we were successful in predicting the pharmacokinetics, especially the AUC for FTD in rats and monkeys after the oral administration of several doses of TPI by means of a numerical calculation to clarify the species speciˆcity based on the diŠerence in the level of expression of TPase between rats and monkeys. In this prediction, we used in vitro kinetic parameters for the metabolism of FTD as well as TPI and in vivo pharmacokinetic parameters for rats and monkeys.
In our predictions, we adopted a perfusion model (Fig. 1) to describe the disposition of FTD in animals following the oral administration of TAS-102. We assumed that all metabolism occurred only in the liver in our modeling (fg.i.＝1 in Eq. (13)). To describe the metabolic interaction between FTD and TPI, MichaelisMenten kinetics were introduced (Eq. (12)).
Furthermore, CL int,h varies with time due to the diŠerent concentrations of FTD and TPI according to Eq. (12) . Equation (12) is composed of two terms. Thê rst term represents FTD metabolism by TPase, which is described by the Michaelis-Menten equation including time-dependent variables such as the concentration of FTD (Cb) and TPI (I). Km, Vmax and Ki were obtained from in vitro experiments ( Table 2) . Since the activity of UPase in rats is relatively high compared to that of TPase, a potent inhibition of FTD metabolism by TPI was not observed in rats, which is not the case in monkeys.
Concerning the renal clearance of FTD, TPI enhanced CLr dose-dependently as shown in Fig. 3 . In the presence of TPI (24 and 14 mg W kg in the rat and monkey, respectively), CL r was higher than CL h in both rats and monkeys. Therefore, we included this eŠect in our model quantitatively.
In a recent report, it was reported that FTD in addition to some antiviral nucleoside analogs was transported via rOAT1 which is a known primary transporter in the tubular secretion of endogenous and exogenous organic anions. 20) In the report, the authors suggested that pyrimidine and purine rings might participate in the interaction of substrates with rOAT1. This suggestion may well explain our observation of the TPI-dependent increase in urinary excretion rate. One possible explanation is that FTY, which is a major metabolite of FTD, may compete with FTD for binding to the recognition site in rOAT1. Based on this hypothesis, it can be assumed that the decrease in FTY as the result of TPI co-administration may induce an enhanced tubular secretion of FTD.
Using the obtained parameters, we simulated time courses for FTD in blood after an oral administration with diŠerent doses of TPI in rats and monkeys (Fig. 4) . The simulation after the oral administration of TAS-102 successfully demonstrated the appropriate time-courses for FTD in both animals, however, in the case of other doses, quite diŠerent responses between rats and monkeys were found, suggesting species speciˆcity in TPase expression levels. Despite the much higher concentration of TPI than the Ki (the mean blood concentrations in rats and monkeys when orally administered 50 and 30 mg W kg of TAS-102 were 429 and 81.2 ng W mL, respectively), systemic clearance in rats was largely unaŠected while the clearance in monkeys was totally suppressed. Therefore, we introduced the term, b, to represent the UPase activities only in case of rats. As shown in Fig. 5 , a remarkable TPI-dependent increase in the AUC for FTD was found in monkeys, while the eŠect of TPI in rats was minimal.
In this study, we successfully explained the species diŠerences for FTD disposition after co-administration with TPI using a quantitative evaluation of the TPI inhibitory eŠect in hepatic metabolism as well as the enhanced eŠect of renal clearance in rats and monkeys. Our pharmacokinetic model will provide useful information in developing a combination of TPI for enhanced bioavailability in humans.
